Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 4Phase 4 2Phase 3 2Phase 2/3 1Phase 1/2 1

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 282Gynecologic 110Breast 64Head & Neck 31CNS 30Genitourinary 27Gastrointestinal 21Other solid neoplasm 10Tumor-Agnostic 8Lymphoid 6Sarcoma 5Dermatologic 4Endocrine 2Other 1Classical hematology 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Head and Neck Neoplasms 1Extrapulmonary Neuroendocrine Cancer 1

Interventions

Everolimus 8lanreotide 7Octreotide 7lutetium Lu 177 dotatate 6pasireotide 5Thyrotropin Alfa 5Mitotane 4Etoposide 4Doxorubicin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Mifepristone 3Filgrastim 3Corlux 3Cisplatin 3Chemotherapy, Adjuvant 3Capecitabine 3Cabergoline 3vandetanib 2telotristat ethyl 2surufatinib 2ribociclib 2fluorodopa F 18 2cabozantinib 2Temozolomide 2Receptor-Like Protein Tyrosine Phosphatases, Class 2 2Lutetium-177 2Lutetium 2Leucovorin 2Iodine-131 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Carboplatin × Endocrine × Clear all
NCT07544654 2026-05-27

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Boehringer Ingelheim

Phase 3 Not yet recruiting
390 enrolled
Endocrine

Extrapulmonary Neuroendocrine Cancer

NCT01701349 2014-05-01

FACT2

Mateon Therapeutics

Phase 3 Withdrawn
EndocrineHead & Neck

Head and Neck Neoplasms, Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡